Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength

Business

Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales. 

Read the original report.

Articles You May Like

Marc Lore’s Wonder bets on Texas, automation and user-built restaurants as it mulls IPO
Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again
Biotech stocks are surging. How investors can play the new drug innovation boom
Midterm elections: How affordability and the economy could affect voters’ decisions
Honda warns 50% Canada auto tariffs would be catastrophic for industry

Leave a Reply

Your email address will not be published. Required fields are marked *